Matrix Asset Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.83M | Sell |
39,070
-105
| -0.3% | -$22.6K | 0.8% | 42 |
|
|
2026
Q1 | $8.52M | Buy |
39,175
+890
| +2% | +$197K | 0.78% | 38 |
|
|
2025
Q4 | $8.75M | Sell |
38,285
-528
| -1% | -$120K | 0.79% | 41 |
|
|
2025
Q3 | $8.99M | Buy |
38,813
+302
| +0.8% | +$61.5K | 0.83% | 44 |
|
|
2025
Q2 | $7.15M | Sell |
38,511
-608
| -2% | -$113K | 0.72% | 43 |
|
|
2025
Q1 | $8.2M | Sell |
39,119
-64,910
| -62% | -$12.6M | 0.9% | 40 |
|
|
2024
Q4 | $18.5M | Buy |
104,029
+2,768
| +3% | +$509K | 2.02% | 19 |
|
|
2024
Q3 | $20M | Sell |
101,261
-43,986
| -30% | -$8.21M | 2.22% | 17 |
|
|
2024
Q2 | $24.9M | Buy |
145,247
+2,291
| +2% | +$380K | 2.97% | 11 |
|
|
2024
Q1 | $26M | Sell |
142,956
-21,471
| -13% | -$3.7M | 3.11% | 9 |
|
|
2023
Q4 | $25.5M | Buy |
164,427
+3,125
| +2% | +$456K | 3.24% | 9 |
|
|
2023
Q3 | $24M | Buy |
161,302
+320
| +0.2% | +$47K | 3.43% | 5 |
|
|
2023
Q2 | $21.7M | Buy |
160,982
+2,972
| +2% | +$436K | 2.99% | 10 |
|
|
2023
Q1 | $25.2M | Sell |
158,010
-449
| -0.3% | -$68.6K | 3.64% | 7 |
|
|
2022
Q4 | $25.6M | Sell |
158,459
-4,245
| -3% | -$651K | 3.84% | 5 |
|
|
2022
Q3 | $21.8M | Buy |
162,704
+14,646
| +10% | +$2.1M | 3.58% | 4 |
|
|
2022
Q2 | $22.7M | Sell |
148,058
-30,824
| -17% | -$4.71M | 3.48% | 10 |
|
|
2022
Q1 | $29M | Sell |
178,882
-54,381
| -23% | -$7.9M | 3.9% | 4 |
|
|
2021
Q4 | $31.6M | Buy |
233,263
+156
| +0.1% | +$18.4K | 4.11% | 4 |
|
|
2021
Q3 | $25.1M | Buy |
233,107
+1,825
| +0.8% | +$209K | 3.54% | 6 |
|
|
2021
Q2 | $26.1M | Buy |
231,282
+22
| +0% | +$2.48K | 3.74% | 4 |
|
|
2021
Q1 | $25M | Buy |
231,260
+3,449
| +2% | +$369K | 3.73% | 4 |
|
|
2020
Q4 | $24.4M | Buy |
227,811
+4,386
| +2% | +$421K | 4.12% | 3 |
|
|
2020
Q3 | $19.6M | Sell |
223,425
-38,261
| -15% | -$3.6M | 3.81% | 4 |
|
|
2020
Q2 | $25.7M | Sell |
261,686
-7,102
| -3% | -$625K | 4.92% | 2 |
|
|
2020
Q1 | $20.5M | Sell |
268,788
-14,322
| -5% | -$1.22M | 4.66% | 4 |
|
|
2019
Q4 | $25.1M | Sell |
283,110
-940
| -0.3% | -$78K | 4.09% | 5 |
|
|
2019
Q3 | $21.5M | Buy |
284,050
+48,040
| +20% | +$3.29M | 3.8% | 5 |
|
|
2019
Q2 | $17.2M | Sell |
236,010
-12,862
| -5% | -$1.01M | 3.04% | 10 |
|
|
2019
Q1 | $20.1M | Buy |
248,872
+1,246
| +0.5% | +$102K | 3.43% | 7 |
|
|
2018
Q4 | $22.8M | Sell |
247,626
-208
| -0.1% | -$18.3K | 4.24% | 3 |
|
|
2018
Q3 | $23.4M | Buy |
247,834
+406
| +0.2% | +$38.5K | 3.74% | 7 |
|
|
2018
Q2 | $22.9M | Sell |
247,428
-2,205
| -0.9% | -$215K | 3.78% | 6 |
|
|
2018
Q1 | $23.6M | Sell |
249,633
-3,839
| -2% | -$422K | 3.9% | 6 |
|
|
2017
Q4 | $24.5M | Sell |
253,472
-7,445
| -3% | -$702K | 3.89% | 5 |
|
|
2017
Q3 | $23.2M | Sell |
260,917
-864
| -0.3% | -$65.8K | 3.82% | 5 |
|
|
2017
Q2 | $19M | Sell |
261,781
-210
| -0.1% | -$14.1K | 3.25% | 9 |
|
|
2017
Q1 | $17.1M | Sell |
261,991
-680
| -0.3% | -$42.8K | 3% | 10 |
|
|
2016
Q4 | $16.4M | Buy |
262,671
+90,091
| +52% | +$5.5M | 2.79% | 11 |
|
|
2016
Q3 | $10.9M | Buy |
172,580
+36,110
| +26% | +$2.34M | 1.92% | 26 |
|
|
2016
Q2 | $8.45M | Buy |
136,470
+59,269
| +77% | +$3.61M | 1.64% | 29 |
|
|
2016
Q1 | $4.41M | Buy |
77,201
+15,855
| +26% | +$884K | 0.87% | 43 |
|
|
2015
Q4 | $3.63M | Buy |
+61,346
| New | +$3.53M | 0.7% | 45 |
|
|
2015
Q3 | – | Sell |
-3,234
| Closed | -$217K | – | 72 |
|
|
2015
Q2 | $217K | Buy |
+3,234
| New | +$211K | 0.03% | 69 |
|
|
2015
Q1 | – | Sell |
-3,234
| Closed | -$212K | – | 79 |
|
|
2014
Q4 | $212K | Buy |
+3,234
| New | +$204K | 0.02% | 71 |
|
Other funds holding ABBV
LMFP
HCM
AAMU
HPC
CRM
CNB
Matrix Asset Advisors's ABBV Position: Q2 2026 in Review
Matrix Asset Advisors reduced its AbbVie (ABBV) stake by 0.27% in Q2 2026, selling an estimated $22.6K and leaving 39,070 shares worth $9.83M. The position accounts for 0.8% of the portfolio, ranked #42.
Matrix Asset Advisors first reported a position in ABBV in Q4 2014 and has held it in 45 quarters since. The position peaked at $31.6M in Q4 2021. 803 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Matrix Asset Advisors held 39,070 shares of AbbVie worth $9.83M as of Q2 2026.
- Matrix Asset Advisors sold 105 AbbVie shares in Q2 2026, an estimated $22.6K.
- AbbVie made up 0.8% of Matrix Asset Advisors's portfolio in Q2 2026, its #42 holding.
- Matrix Asset Advisors first reported a position in AbbVie in Q4 2014 and has held it in 45 quarters since.
- Matrix Asset Advisors's AbbVie position peaked at $31.6M in Q4 2021.
- 803 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Matrix Asset Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.